M. Çakmak, S. B. Kaya, Ö. Bostan, G. Tuncay, E. Damadoğlu, G. Karakaya, A. Kalyoncu
{"title":"1例接受奥玛单抗治疗的重症哮喘患者因COVID-19死亡的病例报告","authors":"M. Çakmak, S. B. Kaya, Ö. Bostan, G. Tuncay, E. Damadoğlu, G. Karakaya, A. Kalyoncu","doi":"10.21911/aai.584","DOIUrl":null,"url":null,"abstract":"Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases There are concerns that COVID-19 will be more severe in patients with severe asthma The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19 To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2020-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report\",\"authors\":\"M. Çakmak, S. B. Kaya, Ö. Bostan, G. Tuncay, E. Damadoğlu, G. Karakaya, A. Kalyoncu\",\"doi\":\"10.21911/aai.584\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases There are concerns that COVID-19 will be more severe in patients with severe asthma The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19 To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma\",\"PeriodicalId\":42004,\"journal\":{\"name\":\"Astim Allerji Immunoloji\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2020-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Astim Allerji Immunoloji\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21911/aai.584\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Astim Allerji Immunoloji","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21911/aai.584","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report
Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases There are concerns that COVID-19 will be more severe in patients with severe asthma The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19 To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma
期刊介绍：
Asthma Allergy Immunology has been published three times a year in April, August and December as the official and periodical journal of the Turkish National Society of Allergy and Clinical Immunology since 2003. All articles published in the journal have been available online since 2003. A peer reviewed system is used in evaluation of the manuscripts submitted to Asthma Allergy Immunology. The official language of the journal is English. The aim of the journal is to present advances in the field of allergic diseases and clinical immunology to the readers. In accordance with this goal, manuscripts in the format of original research, review, case report, articles about clinical and practical applications and editorials, short report and letters to the editor about allergic diseases and clinical immunology are published in the journal. The target reader population of the Asthma Allergy Immunology includes specialists and residents of allergy and clinical immunology, pulmonology, internal medicine, pediatrics, dermatology and otolaryngology as well as physicians working in other fields of medicine interested in allergy and immunological diseases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
